A pharmacokinetics study of edoxaban in non-small cell lung cancer patients harboring EGFR mutation combined with venous thromboembolism
Not Applicable
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000021160
- Lead Sponsor
- Shimane University Faculty of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
History of allergic reaction for edoxavan Severe renal dysfunction (Ccr under 30 mL/min) Severe liver disease Interstitial pneumonia Plannning for concurrent chemoradiotherapy Started medication or treatment for VTE Active bleeding Severe hypertention A pregnant woman, a woman in breast-feeding Taking aspirin or two kind os antiplatelet drug Acute infectious endocarditis An inappropriate case judged by doctor in charge
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pharmacokinetic analysis
- Secondary Outcome Measures
Name Time Method